Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.

Barritt, A Sidney et al.·Alimentary pharmacology & therapeutics·2022·
RPEP-060022022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Liraglutide and semaglutide led to histological resolution of NASH in ~40% to 60% of patients.

Key Numbers

How They Did This

The study involved a review of existing literature and meta-analyses on GLP-1RAs and their effects on NASH.

Why This Research Matters

Understanding the role of GLP-1RAs in treating NASH could provide new therapeutic options for patients with limited treatment choices. This research may lead to improved management of obesity and related metabolic disorders.

What This Study Doesn't Tell Us

The review primarily summarizes existing studies, and the long-term effects and safety of GLP-1RAs in NASH require further investigation.

Trust & Context

Original Title:
Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Published In:
Alimentary pharmacology & therapeutics, 55(8), 944-959 (2022)
Database ID:
RPEP-06002

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06002·https://rethinkpeptides.com/research/RPEP-06002

APA

Barritt, A Sidney; Marshman, Emma; Noureddin, Mazen. (2022). Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. Alimentary pharmacology & therapeutics, 55(8), 944-959. https://doi.org/10.1111/apt.16794

MLA

Barritt, A Sidney, et al. "Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.." Alimentary pharmacology & therapeutics, 2022. https://doi.org/10.1111/apt.16794

RethinkPeptides

RethinkPeptides Research Database. "Review article: role of glucagon-like peptide-1 receptor ago..." RPEP-06002. Retrieved from https://rethinkpeptides.com/research/barritt-2022-review-article-role-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.